Par Drugs and Chemicals Limited (PAR.NS)
- Previous Close
102.73 - Open
97.59 - Bid --
- Ask --
- Day's Range
97.59 - 101.99 - 52 Week Range
81.01 - 348.45 - Volume
14,090 - Avg. Volume
22,855 - Market Cap (intraday)
1.203B - Beta (5Y Monthly) -0.19
- PE Ratio (TTM)
7.81 - EPS (TTM)
12.53 - Earnings Date Aug 1, 2025 - Aug 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 22, 2021
- 1y Target Est
--
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, PARSIL-HT, PAR ADD OP, MagSil OF, FlowSil, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It exports its products to Germany, the United Kingdom, Bangladesh, Iran, the United Arab Emirates, Indonesia, Japan, South Korea, and internationally. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
www.pardrugs.com122
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PAR.NS
View MorePerformance Overview: PAR.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PAR.NS
View MoreValuation Measures
Market Cap
1.26B
Enterprise Value
1.08B
Trailing P/E
8.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.25
Price/Book (mrq)
1.31
Enterprise Value/Revenue
1.07
Enterprise Value/EBITDA
4.42
Financial Highlights
Profitability and Income Statement
Profit Margin
15.20%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.01B
Net Income Avi to Common (ttm)
154.26M
Diluted EPS (ttm)
12.53
Balance Sheet and Cash Flow
Total Cash (mrq)
187.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--